Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q1)Oct 31, 2025 | (FY)Jul 31, 2025 | (Q4)Jul 31, 2025 | (Q3)Apr 30, 2025 | (Q2)Jan 31, 2025 | (Q1)Oct 31, 2024 | (FY)Jul 31, 2024 | (Q4)Jul 31, 2024 | (Q3)Apr 30, 2024 | (Q2)Jan 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -18.45%-543.37K | 39.70%-1.7M | 21.77%-325.77K | 70.95%-272.61K | 10.54%-639.34K | 38.33%-458.75K | -153.61%-2.81M | -183.51%-416.42K | -368.30%-938.29K | -117.90%-714.64K |
| Net income from continuing operations | -11.46%-574.91K | 51.01%-2.06M | 19.53%-984.89K | 66.89%-268.24K | 81.75%-292.38K | 9.73%-515.81K | -198.17%-4.21M | -239.67%-1.22M | -193.19%-810.02K | -240.89%-1.6M |
| Operating gains losses | -101.87%-1.33K | 99.03%-617 | -965.65%-100.87K | --0 | 201.61%29.41K | 10,178.24%70.85K | -746.38%-63.56K | ---9.47K | ---63.14K | --9.75K |
| Depreciation and amortization | -26.10%5.4K | -2.03%28.66K | -18.29%6.03K | 3.93%7.66K | 5.85%7.66K | 0.59%7.31K | 264.13%29.25K | 268.78%7.38K | 262.80%7.37K | 257.64%7.24K |
| Asset impairment expenditure | ---- | 254.79%415.54K | ---- | ---- | ---- | ---- | --117.12K | ---- | ---- | ---- |
| Remuneration paid in stock | --0 | -97.80%19.71K | --0 | --0 | --0 | --19.71K | --894.87K | --0 | --0 | --894.87K |
| Other non cashItems | 0.00%7.92K | -0.28%31.4K | -0.01%7.91K | -1.11%7.66K | 0.01%7.92K | -0.01%7.92K | -72.01%31.49K | -12.38%7.92K | -74.87%7.74K | -78.41%7.92K |
| Change In working capital | 140.13%19.55K | -133.73%-129.85K | -51.72%330.51K | 75.46%-19.7K | -1,111.31%-391.95K | 73.95%-48.72K | 103.90%384.95K | 226.10%684.54K | -286.28%-80.25K | -131.32%-32.36K |
| -Change in receivables | -274.25%-8.1K | -184.07%-4.75K | -114.28%-1.81K | -147.22%-5.51K | 130.30%4.73K | 29.82%-2.16K | 175.07%5.65K | 1,075.56%12.69K | 960.18%11.66K | -588.86%-15.62K |
| -Change in prepaid assets | -1,043.69%-83.55K | 0.88%-10.79K | 28.42%64.61K | -281.14%-78.4K | 67.50%-5.85K | 139.13%8.85K | -122.80%-10.89K | 46.57%50.31K | -132.81%-20.57K | -137.32%-18K |
| -Change in payables and accrued expense | 300.68%111.19K | -144.96%-114.31K | -44.87%267.71K | 190.01%64.21K | -30,849.65%-390.83K | 65.65%-55.41K | 71.15%254.26K | 174.52%485.61K | -290.81%-71.34K | -97.55%1.27K |
| -Change in other working capital | ---- | ---- | ---- | ---- | ---- | ---- | --135.93K | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -18.45%-543.37K | 39.70%-1.7M | 21.77%-325.77K | 70.95%-272.61K | 10.54%-639.34K | 38.33%-458.75K | -153.61%-2.81M | -183.51%-416.42K | -368.30%-938.29K | -117.90%-714.64K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 57.79%-207.88K | -952.51%-138.91K | 0 | 0 | 88.24%-68.97K | -540.78%-492.46K | 82.83%-13.2K | 135.25K | -28.26K |
| Net PPE purchase and sale | --0 | 57.79%-207.88K | -952.51%-138.91K | --0 | --0 | 88.24%-68.97K | -540.78%-492.46K | 82.83%-13.2K | --135.25K | ---28.26K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | 57.79%-207.88K | -952.51%-138.91K | --0 | --0 | 88.24%-68.97K | -540.78%-492.46K | 82.83%-13.2K | --135.25K | ---28.26K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 7.09%805K | -27.49%1.78M | -70.95%133.65K | 920.38%719.23K | 174.6K | -63.88%751.7K | 121.06%2.45M | -58.56%460K | -87.67K | 0 |
| Net issuance payments of debt | ---- | --0 | ---- | ---- | ---- | ---- | --150K | ---- | ---- | ---- |
| Net common stock issuance | 147.37%470K | -17.92%1.84M | --156K | 367.70%759.4K | --736.3K | -90.87%190K | --2.24M | --0 | --162.37K | --0 |
| Cash dividends paid | ---- | --0 | --0 | ---- | ---- | ---- | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | --335K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Interest paid (cash flow from financing activities) | ---- | 55.35%-39.15K | ---12.99K | ---- | ---- | ---- | ---87.67K | --0 | ---- | ---- |
| Net other financing activities | ---- | -115.83%-23.38K | -103.02%-9.36K | ---- | ---- | --561.7K | -86.70%147.63K | --310K | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 7.09%805K | -27.49%1.78M | -70.95%133.65K | 920.38%719.23K | --174.6K | -63.88%751.7K | 121.06%2.45M | -58.56%460K | ---87.67K | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | -40.17%191.6K | -72.67%320.26K | 80.00%525.77K | -93.16%80.55K | -71.83%544.28K | -72.67%320.26K | -5.63%1.17M | 3.07%292.1K | 141.95%1.18M | 136.94%1.93M |
| Current changes in cash | 16.81%261.63K | 85.31%-125.17K | -1,189.71%-331.03K | 150.14%446.62K | 37.44%-464.74K | -70.19%223.98K | -1,018.96%-851.97K | -96.57%30.38K | -344.56%-890.71K | -126.52%-742.9K |
| Effect of exchange rate changes | 153.49%109 | -1,314.29%-3.49K | -41.52%-3.14K | -129.89%-1.4K | 109.01%1.01K | -99.52%43 | -95.35%287 | -196.77%-2.22K | 247.57%4.68K | -1,735.84%-11.22K |
| End cash Position | -16.71%453.34K | -40.17%191.6K | -40.17%191.6K | 80.00%525.77K | -93.16%80.55K | -71.83%544.28K | -72.67%320.26K | -72.67%320.26K | 3.07%292.1K | 141.95%1.18M |
| Free cash from | -2.97%-543.37K | 42.39%-1.9M | -8.16%-464.68K | 66.05%-272.61K | 13.94%-639.34K | 60.33%-527.72K | -178.70%-3.31M | -92.02%-429.62K | -300.80%-803.04K | -126.52%-742.9K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.